Ibogaine binds directly to mu-opioid receptors, resetting their sensitivity to the pre-addiction baseline. Its long-acting metabolite noribogaine continues suppressing cravings and withdrawal signals for weeks afterward. This is not substitution — it is a neurological reset at the source.
Ibogaine binds mu-opioid receptors — the same sites hijacked by opioids — and resets their sensitivity. This interrupts the withdrawal cascade at its neurochemical root, not at the surface. Within hours, the receptors are no longer screaming for opioids.
Ibogaine is metabolized to noribogaine, which has a 28–49 hour half-life. This metabolite continues binding mu-opioid, kappa-opioid, and serotonin transporters for weeks, suppressing cravings and stabilizing mood long after the acute treatment window.
Ibogaine triggers a surge of GDNF (glial cell line-derived neurotrophic factor), a protein that repairs dopaminergic neurons damaged by long-term opioid use. This is why patients describe post-ibogaine clarity and emotional groundedness that persists for months.
From administration to full recovery. Every phase is medically supervised, with physician and nursing staff present around the clock.
Following successful completion of the booster protocol and confirmed medical clearance, the primary ibogaine HCl flood dose is administered. The patient is positioned comfortably in a private treatment room. Cardiac monitoring begins immediately. Vitals are recorded every 30 minutes throughout.
Ibogaine begins crossing the blood-brain barrier. The patient lies down, eyes typically closed or covered. Some experience visual phenomena or deep introspective states. Opioid withdrawal symptoms begin diminishing noticeably. Nausea may occur in some patients during this phase — the medical team is present and prepared.
The peak pharmacological window. Ibogaine is at maximum receptor occupancy. Withdrawal symptoms are dramatically reduced or fully absent for most patients. Many report profound introspective experiences — life review, pattern recognition, emotional clarity. The physician maintains continuous QTc monitoring. This phase requires absolute rest.
Acute withdrawal is essentially gone for the majority of patients. The introspective experience lightens. Psychological insights from the peak phase begin integrating. Light hydration is introduced if tolerated. The patient remains monitored but is typically calm, alert, and profoundly reflective.
The ibogaine experience transitions into the afterglow state. Ibogaine plasma levels decline while noribogaine accumulates. Light nourishment is introduced. Many patients report feeling unusually clear-headed — not groggy or medicated, but genuinely rested and present. Physician evaluates for any post-treatment needs.
No acute withdrawal. The patient is resting, mobile, and oriented. Noribogaine is now the dominant active compound in the body, providing sustained anti-craving and mood-stabilizing effects. Staff transitions to integration support. Most patients describe this window as unexpectedly peaceful.
Energy returns progressively. Appetite normalizes. The 90-day aftercare program begins: microdose ibogaine protocol, physician video consultations, and psychologist support. This critical window determines long-term outcomes — the neuroplasticity window opened by ibogaine is actively leveraged for lasting recovery.
Ibogaine's mechanism operates at the receptor level — making it effective across the full spectrum of opioid dependency. Each substance has nuances in protocol preparation. Our medical team designs every treatment individually.
The most challenging opioid. Still addressable with the right preparation.
The original ibogaine indication. Decades of documented outcomes.
Whether from legitimate medical use or not. Dependency is dependency.
Kratom withdrawal is frequently underestimated. Ibogaine is not.
A methadone taper is non-negotiable. Your safety depends on it.
Suboxone is the one exception requiring a bridge period. We guide you through it.
The numbers tell the story. Compare treatment approaches across the factors that matter most to long-term recovery.
| Factor | Traditional Rehab | MAT (Suboxone) | MindScape Ibogaine |
|---|---|---|---|
| Duration | 30–90 days | Indefinite | 7–12 days |
| Withdrawal | 7–14 days acute | Avoided via substitution | Eliminated in 24–48 hrs |
| Mechanism | Behavioral only | Receptor substitution | Neurological reset |
| Cost | $20,000–$80,000 | $3,000–$12,000 / year | $7,500–$14,500 (one-time) |
| Relapse Rate (Yr 1) | 40–60% | 50%+ on discontinuation | Significantly lower with protocol |
| Root Cause | Not addressed | Not addressed | Directly targeted |
| New Dependency Risk | None | High | None |
| Aftercare | Varies widely | Ongoing prescriptions | 90-day microdose + physician + psychologist |
Most ibogaine clinics administer a single large flood dose and manage the consequences. MindScape starts differently. In the days before your primary treatment, you receive twice-daily ibogaine TA booster doses that progressively build noribogaine levels in your system.
By the time the flood dose is administered, your receptors are already partially stabilized, your metabolism is primed, and our team has direct observational data on how your body processes the molecule. The result: a safer pharmacokinetic curve, lower peak cardiac risk, and a more therapeutically effective outcome.
Read the Full Booster ProtocolIbogaine opens a profound neuroplasticity window. The acute withdrawal is gone. But the brain's reward system needs time and support to fully reestablish healthy patterns. Our 90-day aftercare program exists precisely to leverage this window before it closes.
For most patients, ibogaine begins interrupting the acute withdrawal cascade within 1 to 4 hours of administration. By hours 8 to 16, acute withdrawal symptoms — the muscle cramps, sweating, restlessness, nausea — are dramatically reduced or fully resolved. The 24 to 48 hour window refers to the full elimination of acute withdrawal, not just partial relief. This is fundamentally different from anything achieved by tapering, cold turkey, or substitution drugs.
The ibogaine experience itself is not typically painful. Patients often describe the treatment window as disorienting, deeply introspective, and occasionally uncomfortable in the way a demanding inner journey is uncomfortable — but not physically agonizing. Some nausea may occur during onset, which our medical team manages. The profound irony is that the withdrawal symptoms patients most dread — the shaking, cramping, insomnia — diminish as ibogaine takes effect rather than peaking.
Yes. Fentanyl is the most complex opioid presentation we treat due to its potency, the prevalence of analogs, and its tight receptor binding characteristics. Our protocol for fentanyl patients typically includes an extended booster phase to ensure sufficient noribogaine accumulation before the flood dose. We have successfully treated patients with severe, long-term fentanyl dependency including those who have failed multiple prior detox attempts. The preparation protocol is more intensive — the outcomes are consistent with other opioid presentations.
It depends on your substance. For most opioids — heroin, fentanyl, prescription opioids, kratom — no prior detox is required. You arrive on your current dependency level and we begin the booster protocol from there. The major exceptions are methadone (requires tapering to 30mg or below before arrival) and buprenorphine/Suboxone (requires complete discontinuation for a minimum of 7 to 14 days). Both of these substances interact with ibogaine's mechanism in ways that require careful preparation. Our team guides you through every step of the pre-treatment preparation process.
Suboxone (buprenorphine) is a partial opioid agonist — it occupies the same mu-opioid receptors as heroin or fentanyl, preventing withdrawal by keeping those receptors partially active. This manages withdrawal but creates a new dependency. Suboxone must be taken indefinitely or tapered very slowly; stopping it produces its own withdrawal. Ibogaine is not an opioid agonist. It resets the sensitivity of opioid receptors to their pre-addiction state without activating them in a dependency-producing way. The treatment is given once. There is no ongoing dosing requirement. The goal is to end the dependency cycle entirely, not manage it.
The acute ibogaine experience lasts 24 to 36 hours. But ibogaine's impact extends well beyond the acute window. Its primary metabolite, noribogaine, remains active in the body for several weeks due to its 28 to 49 hour half-life and high affinity for opioid and serotonin receptors. Most patients report significantly reduced or eliminated cravings for weeks to months post-treatment. The neuroplasticity effects — the GDNF and BDNF upregulation that supports neural repair — are sustained for months. Long-term outcomes are substantially improved by participating in the 90-day aftercare program that leverages this neuroplasticity window.
Deepen your understanding before reaching out.